This site is intended for healthcare professionals

FDA grants Emergency Use Authorisation of mRNA-1273 vaccine for children 6 months and older.

Read time: 1 mins
Published:21st Jun 2022

Moderna, Inc. announced that it has received emergency use authorization (EUA) from the FDA for its COVID-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25 µg.

The company has also received emergency use authorization for a 50 ug two-dose regimen of mRNA-1273 for children ages 6 through 11 years old and a 100 ug two-dose regimen for adolescents aged 12 through 17 years old.

The two-dose regimens, with doses tailored for each age group given one month apart, are well-timed to initiate protection for the start of the school year, as children return to higher-risk classroom and daycare settings. mRNA-1273 for children and adolescents showed protection starting 14 days after the second dose. Protection was statistically significant, with data coming from large, well-controlled trials of more than 14,000 children and adolescents and a median follow-up of more than 2 months for 6 months through 5 years of age, 5.6 months for 6 through 11 years of age, and 11.1 months for adolescents.

Condition: Coronavirus/COVID-19 Infection
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights